Scancell's Melanoma Drug Gets FDA Nod for Pivotal Phase 3 Trial

NOTTINGHAM, UK – January 26, 2026 – UK-based biotechnology firm Scancell Holdings has received a critical green light from the U.S. Food and Drug Administration (FDA) for its advanced melanoma therapy, iSCIB1+. The agency cleared the company's Investigational New Drug (IND) application, setting the stage for a global, registrational Phase 3 clinical trial planned to begin in 2026.

This regulatory milestone is a significant validation for Scancell's novel immunotherapy, moving it one step closer to potentially becoming a new standard of care for patients with unresectable late-stage melanoma. The decision follows highly promising data from the company's Phase 2 SCOPE trial, which demonstrated a substantial improvement in patient outcomes when iSCIB1+ was added to existing checkpoint inhibitor treatments.

For the thousands of individuals diagnosed with advanced melanoma each year, the news represents a tangible step forward in a field that, despite recent advances, still faces significant challenges. Approximately half of all patients currently treated with standard immunotherapies either do not respond or eventually see their disease progress, highlighting a pressing unmet medical need.

A New Standard of Care on the Horizon?

The FDA's decision was heavily influenced by the compelling results of the 140-patient Phase 2 SCOPE trial. The study evaluated iSCIB1+ in combination with the current standard-of-care immunotherapy drugs, nivolumab and ipilimumab, in patients with previously untreated, inoperable stage IIIB/IV melanoma.

Data from the trial revealed a remarkable improvement in progression-free survival (PFS), a key measure of how long a patient lives without their cancer getting worse. In a target patient population, iSCIB1+ demonstrated a 74% PFS rate at 16 months. This stands in stark contrast to the historical benchmark of 50% PFS at 11.5 months for patients receiving nivolumab and ipilimumab alone. This represents an interim 24-percentage-point improvement over the current standard of care.

Furthermore, the overall response rate (ORR) for patients receiving the combination therapy in relevant cohorts was 68.6%, a notable increase from the 50% ORR typically seen with the standard checkpoint inhibitor duo. Critically, these positive results were observed without a significant increase in treatment-related toxicity, suggesting a favorable safety profile for the combination.

One of the trial's lead investigators noted the results showed "extremely exciting early signals," emphasizing the therapy's potential for "significant clinical benefit" in a patient group with limited options. The investigator suggested that if these results are replicated in the upcoming Phase 3 study, the treatment could fundamentally "redefine current treatment paradigms" for advanced melanoma.

The benefits remained consistent even in patient subgroups that are traditionally harder to treat, including those with low levels of the PD-L1 protein or with BRAF wild-type tumors, bolstering confidence in the therapy's broad potential efficacy.

The Science Behind the Hope

At the heart of this progress is Scancell's innovative ImmunoBody® platform. Unlike conventional treatments, iSCIB1+ is a next-generation DNA vaccine designed to train the patient's own immune system to recognize and attack cancer cells. It works by delivering a DNA plasmid that encodes for specific melanoma antigens, stimulating a powerful and durable T-cell response against the tumor.

One of the most significant breakthroughs from the Phase 2 study was the identification of a biomarker to predict which patients are most likely to benefit from the treatment. Researchers found that patients with specific human leukocyte antigen (HLA) alleles, which are proteins that help the immune system distinguish between self and non-self, showed a superior response. This discovery is a major step towards personalized cancer therapy.

The HLA typing test is a common and readily available diagnostic, meaning doctors could easily identify the target population, which Scancell estimates includes approximately 80% of all melanoma patients. This enrichment strategy will be employed in the Phase 3 trial to maximize its chances of success by focusing on the most likely responders.

The therapy is administered via a needle-free device that delivers the vaccine intramuscularly, a method that may offer advantages in patient comfort and administration. The FDA's clearance serves not only as an endorsement of the clinical data but also of the quality of Scancell's manufacturing processes and extensive preclinical work.

Navigating the High-Stakes Biotech Gauntlet

While the clinical and scientific news is overwhelmingly positive, the IND clearance also marks the beginning of a new strategic challenge for Scancell: funding a large, expensive, and complex global Phase 3 trial. Such trials can cost hundreds of millions of dollars and require extensive operational expertise.

In the press release, CEO Dr. Phil L'Huillier confirmed the company is exploring all avenues, stating, "We are continuing our dialogue with regulators broadly as we continue to evaluate all financing options, including partnering discussions, for the Phase 3 trial."

The FDA's endorsement significantly strengthens Scancell's negotiating position. The de-risking of iSCIB1+ makes the company a far more attractive partner for large pharmaceutical firms looking to bolster their oncology pipelines. The addressable market is substantial, estimated at around $3 billion for advanced melanoma, with the potential to expand to between $6 billion and $9 billion if the therapy proves effective in earlier-stage adjuvant or neoadjuvant settings.

Industry analysts have noted that while Scancell, like many clinical-stage biotechs, faces financial pressures such as ongoing losses and cash burn, its regulatory and pipeline progress are key value drivers. The company has a track record of forming strategic alliances, having previously licensed two assets from its GlyMab® platform to the international biotechnology leader Genmab A/S, providing a potential blueprint for a future iSCIB1+ partnership.

With a clear regulatory path forward and a validated asset in a high-need area, the focus for Scancell now shifts from clinical discovery to strategic execution. Securing the necessary resources will be the next pivotal step in translating the promise shown in the SCOPE trial into a life-changing therapy for patients worldwide.